Table 1.
Baseline Characteristics of Patients
| Treatment regimen | |
| calcitriol + docetaxel (n) | 34 |
| abarelix + orchiectomy (n) | 12 |
| abarelix + LHRH antagonist (n) | 18 |
| calcitriol + docetaxel + estrumustine (n) | 23 |
| carboplatin + calcitriol (n) | 17 |
| imatinib + zoledronic acid (n) | 15 |
| Total (n) | 119 |
| Median age (range), years | 71.9 (45.8–91.5) |
| ECOG performance status | |
| 0 | 34.5% |
| > 0 | 65.5% |
| Median PSA (range), ng/mL | 80.8 (0.8–2113) |
| Median hemoglobin (range), g/dL | 12.4 (8.4–16.7) |
| Median alkaline phosphatase (range), U/L | 113 (33–1304) |
| Median CRP (range), mg/L | 5.0 (1–311) |
| Metastasis (all sites) | 90.8% |
| Chemotherapy naive | 84.5% |
| Subjects still alive | 10.9% |
| Median follow-up time (range), months | 19.7 (0.9–98.5) |